Here are the 424B prospectus supplements from Ernexa Therapeutics Inc. (ERNA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics Inc. is conducting a reasonable best-efforts public offering of 21,000,000 shares of common stock (or pre-funded warrants in lieu thereof), each paired with a Common Warrant to purchase one share, plus 231,576 Agent’s Shares as compensation to the placement agent. The combined public offering price is $0.50 per share of Common Stock and accompanying Common Warrant, and $0.49 per pre-funded warrant and accompanying Common Warrant, for total gross proceeds of $10,480,000.00 and estimated proceeds before expenses of $10,007,360.00. The Common Warrants have a $0.68 exercise price, are immediately exercisable, and may expire as early as 180 days after public release of first-cohort Phase 1 ERNA-101 data. This is a no-minimum, best-efforts deal, so the company may raise less than the full amount, and investors will not receive refunds. Ernexa is a preclinical synthetic iMSC therapy company that discloses it will not have sufficient capital to fund operations for 12 months without additional financing and highlights substantial ongoing losses and significant business and regulatory risks.